Mr. Zeeshan Saeed reports

QUANTUM BIOPHARMA ENGAGES STOCKS.NEWS FOR INVESTOR RELATIONS, MARKETING SERVICES AND LEAD GENERATION CAMPAIGNS

Quantum Biopharma Ltd. has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC beginning on June 8, 2026.

Pursuant to the agreement, the agency has agreed to communicate information about the company, but not limited to, creating company profiles and media distribution to the financial community, building a digital community with respect to the company, marketing of news distribution and also lead generation campaigns for a period of six months for a fee of $250,000 (U.S.).

The agency is arm's length to the company and neither the agency nor its principals hold an equity interest in the company's securities, either directly or indirectly, or the right to acquire any equity interest.

Rafael Pereira of the agency will be involved in providing the investor relations services to the company. The agency's contact information is as follows: IR Agency LLC, 23 Downing St., Newark, N.J., 07105, USA, info@ir.agency 862-210-5959.

About Quantum Biopharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

We seek Safe Harbor.